Matisse Capital’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Matisse Capital’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$13K	–	152
2021 Q4	$13K	Sell	1,000 -400	-29%	-$6.62K	0.01%	137
2021 Q3	$32K	Hold	1,400	–	–	0.01%	148
2021 Q2	$61K	Sell	1,400 -45	-3%	-$2.51K	0.02%	146
2021 Q1	$104K	Hold	1,445	–	–	0.03%	157
2020 Q4	$62K	Buy	1,445 +45	+3%	+$2.02K	0.02%	155
2020 Q3	$58K	Buy	+1,400	New	+$72.4K	0.02%	142
2020 Q2	–	Sell	-3,828	Closed	-$288K	–	196
2020 Q1	$288K	Buy	3,828 +128	+3%	+$14.7K	0.11%	139
2019 Q4	$509K	Buy	+3,700	New	+$450K	0.36%	57

Other funds holding ORTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Matisse Capital's ORTX Position: Q1 2022 in Review

Matisse Capital sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2022, closing a stake of 1,000 shares — an estimated $13K sold.

Matisse Capital first reported a position in ORTX in Q4 2019 and held it in 8 quarters. The position peaked at $509K in Q4 2019. 61 funds tracked by Wall St. Rank hold ORTX as of Q1 2022.

Matisse Capital reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2022 after selling out during the quarter.
Matisse Capital sold 1,000 Orchard Therapeutics plc American Depositary Shares shares in Q1 2022, an estimated $13K.
Matisse Capital first reported a position in Orchard Therapeutics plc American Depositary Shares in Q4 2019 and held it in 8 quarters.
Matisse Capital's Orchard Therapeutics plc American Depositary Shares position peaked at $509K in Q4 2019.
61 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2022.

Based on Matisse Capital's 13F filing for Q1 2022, filed 12 Apr 2022.